Objectives: The association of vascular risk factors (VRFs) with incidence of Alzheimer's disease (AD) and vascular dementia (VaD) has been well studied. However, the association between VRFs and non-AD dementia is seldom investigated. In this study, we aim to compare the concurrence of VRFs of Lewy body dementia (LBD) to AD.
| INTRODUCTION
Growing evidence has supported the influence of vascular risk factors (VRFs) on incidence of dementia due to Alzheimer's disease (AD) as well as of vascular dementia (VaD) (Biessels & Kappelle, 2005; Fitzpatrick et al., 2009; Forette et al., 2002; Gorelick, 2004; Gudala, Bansal, Schifano, & Bhansali, 2013; Kivipelto et al., 2005; Launer et al., 2000; Luchsinger, Tang, Stern, Shea, & Mayeux, 2001; Luchsinger et al., 2005; Reitz et al., 2010) . A recent meta-analysis summarized the risk of dementia associated with diabetes and reported a 73% increased risk of all dementia, a 56% increase in AD, and an 127% increase in VaD (Gudala et al., 2013) . Midlife VRFs including hypertension, hypercholesterol, obesity, and diabetes are most contributing to late-life incident dementia due to AD (Biessels & Kappelle, 2005; Fitzpatrick et al., 2009; Kivipelto et al., 2005; Luchsinger et al., 2005; Reitz et al., 2010) . Besides, most of the VRFs including hypertension, diabetes, heart disease, dyslipidemia, and smoking are contributing to the incident dementia associated with stroke (Forette et al., 2002; Gorelick, 2004; Launer et al., 2000; Luchsinger et al., 2001) . However, studies on the association between VRFs and Lewy body dementia (LBD) are limited. Previous studies had put more emphasis on the association of VRFs mainly with Parkinson's disease (PD) patients regardless of whether or not they developed dementia, and the results were controversial (Haugarvoll, Aarsland, Wentzel-Larsen, & Larsen, 2005; Papapetropoulos, Villar, & Mash, 2006; Papapetropoulos et al., 2004; Rektor et al., 2009; Schelp, Mendes-Chiloff, Bazan, Paduan, & Pioltini, 2012; Scigliano et al., 2006; Simon, Chen, Schwarzschild, & Ascherio, 2007; Sławek et al., 2008 Sławek et al., , 2010 Toledo et al., 2013) .
Reduced risk factors for vascular disorders were found in patients with PD (Scigliano et al., 2006) or with α-synucleinopathy (Toledo et al., 2013) . Some studies suggested that PD risk was not significantly related to history of hypertension, hypercholesterolemia, or diabetes (Haugarvoll et al., 2005; Schelp et al., 2012; Simon et al., 2007; Sławek et al., 2008 Sławek et al., , 2010 , and other studies showed positive contribution (Papapetropoulos et al., 2004 (Papapetropoulos et al., , 2006 Rektor et al., 2009 ). Although dementia with Lewy bodies (DLB) is the second most common degenerative dementia (Karantzoulis & Galvin, 2013; McKeith et al., 1996) , the study of VRFs associated with DLB is scarce (Boot et al., 2013) . On account of findings on the association of VRFs in Parkinson's disease dementia (PDD) and DLB are still limited, we aim to study and compare the prevalence of various VRFs of DLB and PDD with AD. We propose that DLB and PDD will present with very approximate patterns of association of VRFs because of their similar clinical and pathological manifestation, but association patterns between DLB/PDD and AD will be different.
| METHODS

| Participants
This study is part of a dementia project in central Taiwan (Chiu, Tsai, Chen, Liu, & Lai, 2015) . A consecutive series of patients visited the dementia clinic fulfill the criteria for AD, DLB, or PDD were enrolled, and their demographic and clinical data including VRFs were analyzed in this study. The dementia patients were diagnosed according to the criteria for primary degenerative dementia in the fourth edition of the Diagnostic and Statistic Manual of Mental Disorders (DSM-IV). The DLB patients were diagnosed according to the revised consensus criteria for probable or possible DLB developed by the third report of the DLB consortium (McKeith et al., 2005) . The PDD patients were 
| Assessment tools
The following variables in all participants were analyzed: smoking, diabetes, hypertension, cerebrovascular disease, cardiovascular disease, and blood pressure, sugar, cholesterol, triglycerides, and total lipids. The global severity of dementia is assessed according to the Clinical Dementia Rating (CDR) scale and sum of boxes of CDR (CDR-SB) (Morris, 1993) . Cognitive functions were assessed with the Mini-mental State Examination (MMSE) (Folstein, Folstein, & McHugh, 1975 ) and the Cognitive Abilities Screening Instrument (CASI) (Teng et al., 1994) . Motor functions were assessed with motor score of the Unified Parkinson's Disease Rating Scale (UPDRS-m) (Ballard et al., 1997) . Fluctuation was diagnosed when a clinical history of fluctuation in cognition and a Mayo Fluctuations Composite Score (MFCS) > 2 were both present (Ferman et al., 2004) . Visual hallucinations (VHs) were diagnosed when a clinical history of recurrent VHs and a hallucination subscale in NPI (NPH-H) > 0 were both present (Cummings et al., 1994) . Parkinsonism was diagnosed when at least 2 of the following were present: bradykinesia, tremor, rigidity, and postural insta- 
| Data analysis
The Chinese version of SPSS 19.0 for Windows (IBM, SPSS Inc., Chicago) was used for statistical analyses. Comparisons between DLB, PDD, and AD groups on demographic data, neuropsychological tests, motor score of UPDRS, VHs subscale (frequency x severity) of NPI, the composite scores (frequency x severity) of NPI, and measurements of VRFs were analyzed using one-way ANOVA with either the Bonferroni or Dunnett T3 post hoc analysis according to the homogeneity of variances. Sex, CDR, clinical features, clinical history of VRFs, and current medications were analyzed with the chi-square test. For the comparison of association of VRFs among patients with LBD and AD, we used a multivariable estimate model, and odds ratios (ORs) were adjusted for age, sex, smoking, systolic and diastolic blood pressures, fasting glucose, body mass index, triglyceride, and total cholesterol.
| Ethical consideration
The Committee for Medical Research Ethics of Show Chwan Hospital reviewed the project, and the Data Inspectorate approved it. All participants signed the informed consent when they agreed to join the study.
| RESULTS
A total of 167 patients with complete data were analyzed. Among them, 55 had DLB, 34 had PDD, and 78 had AD. Table 1 The comparisons of the clinical history and medication are summarized in Table 2 . The results showed that history of hypertension and diabetes was lower in PDD than AD [odds ratio (OR) = 0.38].
Atherosclerosis was lower in DLB than AD (OR = 0.26).
The measurements of VRFs are summarized in Table 3 T A B L E 1 Demographic and background characteristics of DLB, PDD, and AD patients
| DISCUSSION
The main finding of this study was that the VRFs associated with DLB and PDD were similar but were distinct from those with AD. By comparing the clinical history of VRFs among three groups, there is no different association among DLB, PDD, and AD. This finding was partially consistent with the results of two recent studies regarding the risk factors for Lewy body disease (Boot et al., 2013; Sławek et al., 2010) . However, the measurements of these factors in our study further demonstrated a different association pattern of VRFs between DLB/PDD and AD. DLB and PDD presented similar pattern and showed lower association with some of the factors compared to AD. This finding is consistent with two previous studies (Scigliano et al., 2006; Sławek et al., 2010; Toledo et al., 2013) . Results from a large case-control study showed reduced risk factors for vascular disorders were found in patients with PD (Scigliano et al., 2006) . A large-scale study of the contribution of cerebrovascular disease in autopsy-confirmed neurodegenerative disease cases revealed that the prevalence of vascular pathology and cerebrovascular disease was reduced in patients with α-synucleinopathy compared to those with Alzheimer's disease (AD) (Toledo et al., 2013) . Among the few researches regarding VRFs as well as metabolic syndrome (MetS), association with Lewy body disease revealed that reduced VRFs were noted in patients with PD (Sławek et al., 2010) . Results of this study also revealed a modest decline of the risk with increasing blood cholesterol levels (Sławek et al., 2010) .
Whether or not systemic or brain vascular diseases contribute to the progression of PD patients to the development of cognitive dysfunction or dementia is still controversial. Some studies of the association of VRFs with PD revealed no significantly contribution of VRFs to the risk of PD or to the progression of PD to PDD (Haugarvoll et al., 2005; Schelp et al., 2012; Simon et al., 2007; Sławek et al., 2008 Sławek et al., , 2010 .
The others provided positive conclusion (Papapetropoulos et al., 2004 (Papapetropoulos et al., , 2006 Rektor et al., 2009) on idiopathic PD patients may aggravate PD severity (Papapetropoulos et al., 2004) and dementia (Papapetropoulos et al., 2006) .
Leaving aside the controversy of contribution of brain or systemic vascular disorders to parkinsonism or dementia, well control of each VRF is important for the prevention of cardiovascular disorders. In older patients and those with significant comorbid illnesses, target of control of each VRF is probably different from that of younger or healthy adults (Huang & Davis, 2015) . Although midlife VRFs are most contributing to late-life incident dementia due to AD or other dementia (Biessels & Kappelle, 2005; Fitzpatrick et al., 2009; Kivipelto et al., 2005; Luchsinger et al., 2005; Reitz et al., 2010) , the lower the better strategy should be utilized very cautiously when it is applied to older patients and those with significant functional limitation such as dementia and parkinsonism. Looser but reasonable targets may prevent the deterioration of cognitive function as well as reduce the incident dementia (Huang & Davis, 2015) . Balance between the prevention of cardiovascular and cerebrovascular diseases and the preservation of cognitive functions deserves more attention when we are considering the target of control of each VRF associated with older patients.
Determination of the most suitable targets of control needs more evidence from further researches of the elderly.
The study has limitations that should be noted. First, the sample size of PDD group in this study is relatively small. Further researches should include a greater number of PDD patients for a better comparison.
Second, our research was conducted in only one hospital in central Taiwan. Therefore, selection bias may arise, and our findings may not be generalizable to all patients with DLB, PDD, or AD. Future studies should target recruitment of dementia patients from multiple centers in order to reduce the selection bias. Third, the comparison of VRFs between DLB, PDD, and AD in our study was cross-sectional. Therefore, causal relationship of VRFs and dementia is not able to be speculated. Fourth, because of the lack of more determinative equipment or facilities, such as genetic study, dopamine transporter uptake imaging, amyloid plaque imaging, CSF biomarkers, or pathological studies, the diagnosis of DLB, PDD, and AD was based only on clinical criteria. Therefore, diagnosis bias may arise. Future studies should include longitudinal as well as pathological data in order to investigate the contribution of VRFs to LBD.
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